Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-In-Human Phase 1b/2a Dose Escalation Study of EG110A, Administered by Intradetrusor Injections to Adult Participants With Neurogenic Detrusor Overactivity-related Incontinence Following Spinal Cord Injury Who Regularly Perform Clean Intermittent Catheterization

NCT06596291 is registered in ClinicalTrials.gov with Cyllene Therapeutics as lead sponsor.

NCT NCT06596291
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06596291 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-In-Human Phase 1b/2a Dose Escalation Study of EG110A, Administered by Intradetrusor Injections to Adult Participants With Neurogenic Detrusor Overactivity-related Incontinence Following Spinal Cord Injury Who Regularly Perform Clean Intermittent Catheterization
Lead sponsor
Cyllene Therapeutics
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 8, 2025
Completion date
June 30, 2027
Enrollment
16 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

neurogenic detrusor overactivity, spinal cord injuries